TapewireFind a company

person · Reporting owner

Mahadevia Ankit

Disclosed activity across 1 company

Tapewire entity
75825
SEC CIK
0001720974

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Spero Therapeutics, Inc.SPRO · Entity 7014DirectorAugust 28, 2025September 03, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Spero Therapeutics, Inc.

Report date August 28, 2025 · Filed September 03, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect703,294 Reported balance After 2025-08-28 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2025-08-28 · Sale · Disposed 6,572 · Balance 703,294

F1: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of restricted stock unit ("RSUs") that were granted to the Reporting Person on August 26, 2021.

F2: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Filing footnotes · ownership attribution and instrument terms

F1: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of restricted stock unit ("RSUs") that were granted to the Reporting Person on August 26, 2021.

F2: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 28, 2025 Filed Sep 3, 2025 10:04 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 6,572 $1.97 $12,946.84
Disclosure

SEC source: 0000950170-25-112661 · ownership.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 703,294

F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of restricted stock unit ("RSUs") that were granted to the Reporting Person on August 26, 2021.

F1 · shares: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of restricted stock unit ("RSUs") that were granted to the Reporting Person on August 26, 2021.

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
June 12, 2025 Filed Jun 17, 2025 00:32 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 GrantCommon Stock 20,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-087021 · ownership.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 709,866

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 12, 2026, subject to the Reporting Person's continued service through the applicable vesting date.

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
February 05, 2025 Filed Feb 6, 2025 01:30 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 55,260 $0.78 $43,102.80
Disclosure

SEC source: 0000950170-25-014849 · ownership.xml · nonDerivative · entry 2

Mahadevia Ankit · CIK 0001720974 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 689,866

F3 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2023.

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
February 05, 2025 Filed Feb 6, 2025 01:30 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 13,959 $0.78 $10,888.02
Disclosure

SEC source: 0000950170-25-014849 · ownership.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 745,126

F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2022.

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
August 27, 2024 Filed Aug 29, 2024 22:43 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 5,912 $1.35 $7,981.20
Disclosure

SEC source: 0000950170-24-102000 · ownership.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 759,085

F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations pursuant to a "sell to cover" provision included in each RSU Agreement in connection with the vesting of RSUs that were granted to the Reporting Person on August 26, 2021.

Read SEC document
May 29, 2024 Filed May 30, 2024 20:25 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 GrantCommon Stock 20,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-066625 · ownership.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 764,997

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on May 29, 2025, subject to the Reporting Person's continued service through the applicable vesting date.

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
February 02, 2024 Filed Feb 6, 2024 01:50 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 63,795 $1.37 $87,399.15
Disclosure

SEC source: 0000950170-24-011496 · ownership.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 744,997

F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") that were granted to the Reporting Person on February 1, 2022 pursuant to a "sell to cover" provision included in the RSU Agreement.

F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $1.36 to $1.42 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

F3 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
October 05, 2023 Filed Oct 10, 2023 21:18 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 GrantCommon Stock 20,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-052692 · ownership.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 808,792

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on October 5, 2024, subject to the Reporting Person's continued service through the applicable vesting date.

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
August 28, 2023 Filed Aug 30, 2023 20:21 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 9,040 $1.26 $11,390.40
Disclosure

SEC source: 0000950170-23-045442 · ownership.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 788,792

F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") that were granted to the Reporting Person on August 26, 2021 pursuant to a "sell to cover" provision included in the RSU Agreement.

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
February 03, 2023 Filed Feb 6, 2023 21:15 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 12,286 $1.81 $22,237.66
Disclosure

SEC source: 0000899243-23-004039 · doc4.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 797,832

F1 · kind: The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") that were granted to the Reporting Person on February 1, 2022 pursuant to a "sell to cover" provision included in the RSU Agreement.

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 691,205 RSUs held by the Reporting Person.

Read SEC document
February 01, 2023 Filed Feb 4, 2023 00:38 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 GrantCommon Stock 531,914 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-003939 · doc4.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 810,118

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2024, subject to the Reporting Person's continued service through the applicable vesting date.

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 691,205 RSUs held by the Reporting Person.

Read SEC document
February 01, 2022 Filed Feb 3, 2022 21:18 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 GrantStock Option (Right to Buy) · Derivative 187,730 $0.00 Strike: $11.18 $0.00
Disclosure

SEC source: 0000899243-22-004591 · doc4.xml · derivative · entry 2

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,730

Underlying: Common Stock · 187,730 shares

Expires 2032-02-01

F3 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 1, 2023, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
February 01, 2022 Filed Feb 3, 2022 21:18 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 GrantCommon Stock 134,168 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-004591 · doc4.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 278,204

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continued service through the applicable vesting date.

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 212,387 RSUs held by the Reporting Person.

Read SEC document
December 27, 2021 Filed Dec 29, 2021 23:26 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionStock Option (Right to Buy) · Derivative 8,000 $0.00 Strike: $5.90 $0.00
Disclosure

SEC source: 0000899243-21-050049 · doc4.xml · derivative · entry 3

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 486,809

Underlying: Common Stock · 8,000 shares

Expires 2027-07-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
December 27, 2021 Filed Dec 29, 2021 23:26 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 8,000 $14.58 $116,666.40
Disclosure

SEC source: 0000899243-21-050049 · doc4.xml · nonDerivative · entry 2

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,036

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 8,000 shares).

F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.77 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 78,219 restricted stock units ("RSUs") held by the Reporting Person. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 26, 2022, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
December 27, 2021 Filed Dec 29, 2021 23:26 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionCommon Stock 8,000 $5.90 $47,200.00
Disclosure

SEC source: 0000899243-21-050049 · doc4.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,036

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 8,000 shares).

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 78,219 restricted stock units ("RSUs") held by the Reporting Person. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 26, 2022, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
August 26, 2021 Filed Aug 30, 2021 20:15 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 GrantCommon Stock 78,219 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-034502 · doc4.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,036

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 26, 2022, subject to the Reporting Person's continued service through the applicable vesting date.

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
February 01, 2021 Filed Feb 4, 2021 00:44 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 GrantStock Option (Right to Buy) · Derivative 179,319 $0.00 Strike: $19.18 $0.00
Disclosure

SEC source: 0000899243-21-004783 · doc4.xml · derivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 179,319

Underlying: Common Stock · 179,319 shares

Expires 2031-02-01

F1 · derivative.exercise_date: The shares underlying this option vest as to 25% on February 1, 2022, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
November 04, 2020 Filed Nov 6, 2020 00:00 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionStock Option (Right to Buy) · Derivative 7,370 $0.00 Strike: $5.90 $0.00
Disclosure

SEC source: 0000899243-20-030490 · doc4.xml · derivative · entry 6

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 494,809

Underlying: Common Stock · 7,370 shares

Expires 2027-07-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
November 04, 2020 Filed Nov 6, 2020 00:00 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 7,370 $14.43 $106,335.10
Disclosure

SEC source: 0000899243-20-030490 · doc4.xml · nonDerivative · entry 4

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,817

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 9,507 shares).

F4 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.63 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
November 04, 2020 Filed Nov 6, 2020 00:00 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionCommon Stock 7,370 $5.90 $43,483.00
Disclosure

SEC source: 0000899243-20-030490 · doc4.xml · nonDerivative · entry 3

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,187

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 9,507 shares).

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
November 03, 2020 Filed Nov 6, 2020 00:00 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionStock Option (Right to Buy) · Derivative 2,137 $0.00 Strike: $5.90 $0.00
Disclosure

SEC source: 0000899243-20-030490 · doc4.xml · derivative · entry 5

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 502,179

Underlying: Common Stock · 2,137 shares

Expires 2027-07-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
November 03, 2020 Filed Nov 6, 2020 00:00 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 2,137 $14.27 $30,489.65
Disclosure

SEC source: 0000899243-20-030490 · doc4.xml · nonDerivative · entry 2

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,817

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 9,507 shares).

F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.35 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
November 03, 2020 Filed Nov 6, 2020 00:00 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionCommon Stock 2,137 $5.90 $12,608.30
Disclosure

SEC source: 0000899243-20-030490 · doc4.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,954

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 9,507 shares).

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
October 23, 2020 Filed Oct 27, 2020 21:32 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionStock Option (Right to Buy) · Derivative 20 $0.00 Strike: $5.90 $0.00
Disclosure

SEC source: 0000899243-20-029328 · doc4.xml · derivative · entry 3

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 504,316

Underlying: Common Stock · 20 shares

Expires 2027-07-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
October 23, 2020 Filed Oct 27, 2020 21:32 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 20 $14.25 $285.00
Disclosure

SEC source: 0000899243-20-029328 · doc4.xml · nonDerivative · entry 2

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,817

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 20 shares).

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
October 23, 2020 Filed Oct 27, 2020 21:32 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionCommon Stock 20 $5.90 $118.00
Disclosure

SEC source: 0000899243-20-029328 · doc4.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,837

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 20 shares).

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
October 14, 2020 Filed Oct 16, 2020 00:24 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionStock Option (Right to Buy) · Derivative 105 $0.00 Strike: $5.90 $0.00
Disclosure

SEC source: 0000899243-20-028430 · doc4.xml · derivative · entry 6

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 504,336

Underlying: Common Stock · 105 shares

Expires 2027-07-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
October 14, 2020 Filed Oct 16, 2020 00:24 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 105 $14.25 $1,496.25
Disclosure

SEC source: 0000899243-20-028430 · doc4.xml · nonDerivative · entry 4

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,817

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 14,472 shares).

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
October 14, 2020 Filed Oct 16, 2020 00:24 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionCommon Stock 105 $5.90 $619.50
Disclosure

SEC source: 0000899243-20-028430 · doc4.xml · nonDerivative · entry 3

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,922

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 14,472 shares).

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
October 13, 2020 Filed Oct 16, 2020 00:24 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionStock Option (Right to Buy) · Derivative 14,367 $0.00 Strike: $5.90 $0.00
Disclosure

SEC source: 0000899243-20-028430 · doc4.xml · derivative · entry 5

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 504,441

Underlying: Common Stock · 14,367 shares

Expires 2027-07-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
October 13, 2020 Filed Oct 16, 2020 00:24 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 14,367 $14.28 $205,212.48
Disclosure

SEC source: 0000899243-20-028430 · doc4.xml · nonDerivative · entry 2

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,817

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 14,472 shares).

F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.52 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
October 13, 2020 Filed Oct 16, 2020 00:24 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionCommon Stock 14,367 $5.90 $84,765.30
Disclosure

SEC source: 0000899243-20-028430 · doc4.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,184

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 14,472 shares).

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
September 08, 2020 Filed Sep 11, 2020 01:51 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionStock Option (Right to Buy) · Derivative 774 $0.00 Strike: $5.90 $0.00
Disclosure

SEC source: 0000899243-20-024865 · doc4.xml · derivative · entry 3

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 518,808

Underlying: Common Stock · 774 shares

Expires 2027-07-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
September 08, 2020 Filed Sep 11, 2020 01:51 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 774 $14.25 $11,029.73
Disclosure

SEC source: 0000899243-20-024865 · doc4.xml · nonDerivative · entry 2

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,817

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 774 shares).

F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.26 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
September 08, 2020 Filed Sep 11, 2020 01:51 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionCommon Stock 774 $5.90 $4,566.60
Disclosure

SEC source: 0000899243-20-024865 · doc4.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,591

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 774 shares).

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
July 09, 2020 Filed Jul 9, 2020 22:48 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionStock Option (Right to Buy) · Derivative 2,293 $0.00 Strike: $5.90 $0.00
Disclosure

SEC source: 0000899243-20-018847 · doc4.xml · derivative · entry 6

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 519,582

Underlying: Common Stock · 2,293 shares

Expires 2027-07-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
July 09, 2020 Filed Jul 9, 2020 22:48 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 2,293 $14.31 $32,806.64
Disclosure

SEC source: 0000899243-20-018847 · doc4.xml · nonDerivative · entry 4

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,817

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 3,047 shares).

F4 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.37 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
July 09, 2020 Filed Jul 9, 2020 22:48 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionCommon Stock 2,293 $5.90 $13,528.70
Disclosure

SEC source: 0000899243-20-018847 · doc4.xml · nonDerivative · entry 3

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,110

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 3,047 shares).

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
July 07, 2020 Filed Jul 9, 2020 22:48 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionStock Option (Right to Buy) · Derivative 754 $0.00 Strike: $5.90 $0.00
Disclosure

SEC source: 0000899243-20-018847 · doc4.xml · derivative · entry 5

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 521,875

Underlying: Common Stock · 754 shares

Expires 2027-07-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
July 07, 2020 Filed Jul 9, 2020 22:48 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 754 $14.25 $10,744.95
Disclosure

SEC source: 0000899243-20-018847 · doc4.xml · nonDerivative · entry 2

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,817

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 3,047 shares).

F3 · price: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.285 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
July 07, 2020 Filed Jul 9, 2020 22:48 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionCommon Stock 754 $5.90 $4,448.60
Disclosure

SEC source: 0000899243-20-018847 · doc4.xml · nonDerivative · entry 1

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,571

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 3,047 shares).

F2 · balance_after: Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
June 25, 2020 Filed Jun 30, 2020 01:21 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionStock Option (Right to Buy) · Derivative 2,642 $0.00 Strike: $5.90 $0.00
Disclosure

SEC source: 0001209191-20-039352 · doc4.xml · derivative · entry 12

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 522,629

Underlying: Common Stock · 2,642 shares

Expires 2027-07-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
June 25, 2020 Filed Jun 30, 2020 01:21 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 2,642 $14.25 $37,650.35
Disclosure

SEC source: 0001209191-20-039352 · doc4.xml · nonDerivative · entry 8

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,817

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares).

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
June 25, 2020 Filed Jun 30, 2020 01:21 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionCommon Stock 2,642 $5.90 $15,587.80
Disclosure

SEC source: 0001209191-20-039352 · doc4.xml · nonDerivative · entry 7

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,459

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares).

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
June 24, 2020 Filed Jun 30, 2020 01:21 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionStock Option (Right to Buy) · Derivative 3,880 $0.00 Strike: $5.90 $0.00
Disclosure

SEC source: 0001209191-20-039352 · doc4.xml · derivative · entry 11

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 525,271

Underlying: Common Stock · 3,880 shares

Expires 2027-07-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
June 24, 2020 Filed Jun 30, 2020 01:21 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 3,880 $14.28 $55,419.59
Disclosure

SEC source: 0001209191-20-039352 · doc4.xml · nonDerivative · entry 6

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,817

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares).

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
June 24, 2020 Filed Jun 30, 2020 01:21 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionCommon Stock 3,880 $5.90 $22,892.00
Disclosure

SEC source: 0001209191-20-039352 · doc4.xml · nonDerivative · entry 5

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,697

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares).

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document
June 23, 2020 Filed Jun 30, 2020 01:21 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 Exercise / conversionStock Option (Right to Buy) · Derivative 8,045 $0.00 Strike: $5.90 $0.00
Disclosure

SEC source: 0001209191-20-039352 · doc4.xml · derivative · entry 10

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 529,151

Underlying: Common Stock · 8,045 shares

Expires 2027-07-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

Read SEC document
June 23, 2020 Filed Jun 30, 2020 01:21 UTC Spero Therapeutics, Inc. SPRO · Entity 7014 SaleCommon Stock 8,045 $14.33 $115,263.93
Disclosure

SEC source: 0001209191-20-039352 · doc4.xml · nonDerivative · entry 4

Mahadevia Ankit · CIK 0001720974 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,817

F1 · kind: All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 17,180 shares).

F2 · balance_after: Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.